Retrieve all available abstracts of the following 130 articles: HTML format
Single Articles
LI X, Wang J, Wang K, Tan S, et al Analysis of risk factors for postoperative bladder cancer in patients with upper
tract urothelial carcinoma and construction of nomogram prediction model.
BMC Urol. 2025;25:247. PubMed Abstract available
SCHAFER JM, Song NJ, Xiao T, Gauntner TD, et al T cell subsets of urine-derived lymphocytes (UDLs) serve as an indicator of TILs
and reflect immunological sex differences in bladder cancer.
J Immunother Cancer. 2025;13:e012050. PubMed Abstract available
LIN L, Kong L, Dong X, Ma S, et al Sevoflurane suppresses growth and metastasis of bladder cancer cells via inducing
ferroptosis and antitumor microenvironment through Akt/mTOR/SREBP1 signaling.
Chem Biol Interact. 2025 Oct 1:111766. doi: 10.1016/j.cbi.2025.111766. PubMed Abstract available
CHEN W, Song L, Luo J, Tang J, et al Uranalysis-tailored fluorogenic strategy for monitoring bladder cancer biomarker
hyaluronidase-1 by harnessing hydrogen-bonding-induced emission.
Biosens Bioelectron. 2025;291:118060. PubMed Abstract available
SUNGUR U, Kerim Ozfiliz N, Eksi M, Kargi T, et al Assessing the use of modified 5-item frailty index as a prognostic marker of
long-term survival and perioperative outcomes after radical cystectomy
for bladder cancer.
Ir J Med Sci. 2025 Oct 3. doi: 10.1007/s11845-025-04108. PubMed Abstract available
CHEN X, Jiang K, Chen K, An Y, et al HOXB7 drives bladder cancer progression via H-Ras/ERK signaling: a potential
therapeutic target and prognostic biomarker.
Front Oncol. 2025;15:1645803. PubMed Abstract available
MIYAKE M, Tokumaru J, Oi H, Kitagawa H, et al Real-world use of maintenance bacillus Calmette-Guerin therapy in patients with
non-muscle-invasive bladder cancer in Japan: ASUKA study.
BJUI Compass. 2025;6:e70091. PubMed Abstract available
ZHU Z, Zhu Y, Ying W, Wu H, et al Comparison of the anti-reflux ileum valve-pouch orthotopic neobladder and the
Studer technique after radical cystecomy: surgical and renal functional outcomes.
World J Surg Oncol. 2025;23:359. PubMed Abstract available
KANG C, Lee J, Baek MG, Kim NE, et al Urinary microbiome in non-muscle invasive bladder cancer: impact of sample types
and sex differences.
BMC Microbiol. 2025;25:623. PubMed Abstract available
AZHAR Z, Sadia Z Inlexzo (gemcitabine intravesical system): promising data but key questions
remain.
World J Urol. 2025;43:586. PubMed Abstract available
BAGHERZADEH S, Roohollahi F, Kopparapu S, Carballo Cuello CM, et al Posterior-only total en bloc spondylectomy of L4 for solitary bladder cancer
metastasis - An illustrative case.
Surg Neurol Int. 2025;16:360. PubMed Abstract available
CAYUELA L, Achaval V, Cabrera Fernandez S, Ortega Calvo M, et al Sex-specific bladder cancer incidence trends and generational effects in Spain.
Actas Urol Esp (Engl Ed). 2025 Sep 29:501863. doi: 10.1016/j.acuroe.2025.501863. PubMed Abstract available
PUBLISHER T Correction. Current status of management and outcomes of muscle-invasive bladder
cancer in Yemen: a retrospective observational study.
Arch Ital Urol Androl. 2025;97:14449. PubMed Abstract available
NIZAM A, Nguyen CB, Li J, Zabor EC, et al Treatment-Related Adverse Events and Associated Outcomes in Patients With
Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the
UNITE Study.
Cancer Med. 2025;14:e71284. PubMed Abstract available
HOSSEINI AS, Jalali SM, Shateri Z, Shoja M, et al The association between digestion-resistant and bioactive peptide content of
dairy products and bladder cancer: a case-control study.
J Health Popul Nutr. 2025;44:336. PubMed Abstract available
TSUKADA H, Hayakawa N, Sasaki M, Matsubara K, et al [Vaginal and Vulval Secondary Extramammary Paget's Disease Associated with
Urothelial Carcinoma in Situ : A Case Report].
Hinyokika Kiyo. 2025;71:301-305. PubMed Abstract available
CATAL MN, Akarken I, Dere Y, Deliktas H, et al Prognostic difference of molecular subtypes in non-muscle invasive bladder
cancer.
Medicine (Baltimore). 2025;104:e44808. PubMed Abstract available
HU A, Hu C, Lin Y, Zhu X, et al Causal relationship between immune cells and bladder cancer: A bidirectional
Mendelian randomization study.
Medicine (Baltimore). 2025;104:e44268. PubMed Abstract available
LI H, Liang Y, Tang J, Luo H, et al YBX1 Enhances the Stability of TM4SF1 in an m5C-Dependent Manner to Promote
Bladder Cancer Proliferation and Glycolysis.
Comb Chem High Throughput Screen. 2025. PubMed Abstract available
HE J, Dong C, Song X, Bao X, et al MFSD12, transcriptionally regulated by PLAGL2, promotes bladder cancer
progression.
Commun Biol. 2025;8:1402. PubMed Abstract available
SILVA IM, Vacario BGL, Maraslis FT, Koike A, et al GLRX2 polymorphism and oxidative stress levels impact urothelial bladder cancer
outcomes.
Sci Rep. 2025;15:34041. PubMed Abstract available
AMPARO TR, da Anunciacao KF, Almeida TC, de Oliveira AB, et al Lapachol interferes with the cell cycle and inhibits proliferation and migration
of bladder tumor cells with effects on ncRNA expression.
Sci Rep. 2025;15:33829. PubMed Abstract available
ELSALEM L, Aleikish AA, Al-Azzam N, Alfaqih MA, et al Serum xanthine oxidoreductase and oxidative stress are associated with bladder
cancer: a case-control study from Jordan.
J Appl Biomed. 2025;23:107-116. PubMed Abstract available
WANG Y, Zhou T, Hu C, Chen H, et al Prognostic analysis and immunotherapy prediction based on key receptor-ligand
pairs of bladder cancer.
Discov Oncol. 2025;16:1784. PubMed Abstract available
MA X, Quan C Identification of KIF14 as a ferroptosis biomarker for predicting the prognosis
and immunotherapy efficacy of bladder cancer.
Discov Oncol. 2025;16:1786. PubMed Abstract available
ESCOBAR D, Zahir M, Doshi C, Daneshmand S, et al Management of clinical stage T3/T4 bladder cancer: a review.
World J Urol. 2025;43:583. PubMed Abstract available
CUPRYCH-BELTER M, Lupicka-Slowik A, Anisiewicz A, Michaelis M, et al Distinct adaptive strategies to cisplatin, vinblastine and gemcitabine in a panel
of chemoresistant bladder cancer cell lines.
Cancer Drug Resist. 2025;8:49. PubMed Abstract available
ZHOU Z, Chen Y, Wang Z, Yang S, et al Characterization of cancer-related fibroblasts in bladder cancer and construction
of CAFs-based bladder cancer classification: insights from single-cell and
multi-omics analysis.
Front Immunol. 2025;16:1580986. PubMed Abstract available
WANG L, Chang Z, Chen SY, Yang JW, et al Multi-omics dissection of fatty acid metabolism heterogeneity identifies PRDX1 as
a prognostic marker in bladder cancer.
Front Immunol. 2025;16:1669822. PubMed Abstract available
HURLE R, Capalbo A, Lughezzani G, Buffi NM, et al Germline homologous recombination repair (gHRR) variants in bladder cancer:
Preliminary evidence and clinical implications.
BJUI Compass. 2025;6:e70077. PubMed Abstract available
GORSKI J, Gajewski W, Ziembicki H, Pierudzka W, et al Nanoparticles as Drug Delivery Systems in Intravesical Therapy for Non-muscle
Invasive Bladder Cancer: A Narrative Review.
Cureus. 2025;17:e91103. PubMed Abstract available
HERRANZ R, Oto J, Plana E, Perez-Ardavin J, et al Analysis of the Fragmentation and Integrity of Urine Cell-Free DNA as Diagnostic
and Staging Biomarker for Bladder Cancer.
J Mol Diagn. 2025 Sep 26:S1525-1578(25)00222. PubMed Abstract available
OKE I, Lenert A, Swick BL, Lenert P, et al Eosinophilic Fasciitis in a 78-Year-Old Man Following Pembrolizumab Treatment for
Bladder Cancer.
Am J Case Rep. 2025;26:e948323. PubMed Abstract available
EID S, Al-Yousef AS, Kim KW, Yoon S, et al State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced
Bladder Cancer.
Korean J Radiol. 2025;26:959-972. PubMed Abstract available
KABUNDA J, Ndlovu H, Singh K, Sibiya S, et al Nectin-4, Bladder Cancer, and Nuclear Medicine: A Theranostic Frontier.
Semin Nucl Med. 2025 Sep 26:S0001-2998(25)00118. PubMed Abstract available
QAISAR R, Hussain S, Ahmad F, Karim A, et al Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based
chemotherapy and radical cystectomy in muscle-invasive bladder cancer.
Int J Clin Oncol. 2025 Sep 27. doi: 10.1007/s10147-025-02890. PubMed Abstract available
AKYUZ M, Kayar R, Ozsoy E, Artuk I, et al Impact of the CALLY Index in Predicting Overall Survival and Disease-Free
Survival in Patients Undergoing Radical Cystectomy for Muscle-Invasive Bladder
Cancer.
Niger J Clin Pract. 2025;28:1090-1096. PubMed Abstract available
SU M, Chen W, Luo J, Li X, et al E2F1-induced transcriptional activation of MAL2 inhibits sunitinib sensitivity
and promotes the malignant progression of bladder cancer.
J Chemother. 2025 Sep 26:1-12. doi: 10.1080/1120009X.2025.2561275. PubMed Abstract available
REMMELINK MJ, Bloemen PR, van der Voorn P, Attendu X, et al Ex Vivo Optical Coherence Tomography Analysis of Resected Human Bladder with a
Forward-Looking Microelectromechanical Systems Mirror-Based Catheter.
Sensors (Basel). 2025;25:5794. PubMed Abstract available
PEREIRA M, Vale N Exploring Potential for Repurposing Antiretroviral Drugs Etravirine and Efavirenz
in Prostate and Bladder Cancer.
Pharmaceuticals (Basel). 2025;18:1404. PubMed Abstract available
SAKAI AH, Pereira ER, Santos AGPD, Quadreli DH, et al miR-25-3p Modulates Tumor Aggressiveness and Ferroptosis Escape in T24 Bladder
Cancer Cells In Vitro.
Pharmaceuticals (Basel). 2025;18:1382. PubMed Abstract available
CUSUMANO C, Squillante F, Roma M, Miano R, et al Bladder Cancer: Uncovering the Predictive Role of NOTCH as an Emerging Candidate
Biomarker for Therapeutic Strategies.
Cancers (Basel). 2025;17:3078. PubMed Abstract available
JURIC I, Fink EE, Qiu H, Desprez PE, et al Single-cell RNA-sequencing of BCG naive and recurrent non-muscle invasive bladder
cancer reveals a CD6/ALCAM-mediated immune-suppressive pathway.
NPJ Precis Oncol. 2025;9:318. PubMed Abstract available
HUANG X, Meng Y, Song J, Zhu Y, et al Identification of biomarkers associated with mitophagy in bladder cancer.
Sci Rep. 2025;15:33272. PubMed Abstract available
OBAID K, Akpinar C, Karaburun MC, Ibis MA, et al A randomized prospective trial comparing Bacillus Calmette-Guerin (BCG) RIVM and
Russian strains in non-muscle invasive bladder cancer: Efficacy and side effects.
Urol Oncol. 2025 Sep 25:S1078-1439(25)00349. PubMed Abstract available
TITUS RS, Mundra V, Velasquez EL, Xu J, et al The association between prior pelvic radiotherapy for cancer and surgical
outcomes in patients undergoing radical cystectomy for bladder cancer: An
analysis of national surgical quality improvement program targeted cystectomy
database.
Urol Oncol. 2025 Sep 25:S1078-1439(25)00342. PubMed Abstract available
LAI S, Wu P, Liu J, Song Y, et al ASO Author Reflections: Navigating the Dual Threat-Bladder Cancer's Impact on
Upper Tract Urothelial Carcinoma Outcomes.
Ann Surg Oncol. 2025 Sep 26. doi: 10.1245/s10434-025-18004. PubMed
MENG L, Khorasanchi A, Jain R Advancing Bladder Cancer Management: The Role of Neoadjuvant and Adjuvant
Therapies and Biomarkers in Muscle Invasive Bladder Cancer.
Curr Treat Options Oncol. 2025 Sep 26. doi: 10.1007/s11864-025-01355. PubMed Abstract available
LIU J, Zhang Z, Huang B, Fang Y, et al A GRK5 centered prognostic framework for bladder cancer based on palmitoylation
and epigenetic regulation.
Discov Oncol. 2025;16:1735. PubMed Abstract available
KRAEVSKA E, Popovska S Immunohistochemistry-Based Molecular Profiling of Muscle-Invasive Bladder Cancer:
Analysis of 100 Consecutive Cases with Morphological Correlation.
Med Sci (Basel). 2025;13:202. PubMed Abstract available
WANG L, Wang Y, Wang Y, Wang Z, et al Prognostic value and molecular mechanism of photodynamic therapy and apoptosis
related gene FGFR1 in bladder cancer.
Front Oncol. 2025;15:1578695. PubMed Abstract available
TANG Q, Li Y, Liu K, Huang G, et al Development and validation of a risk prediction model for distant metastasis in
muscle-invasive bladder cancer: a retrospective study integrating SEER data with
external validation cohort and biomarker analysis.
Front Oncol. 2025;15:1607173. PubMed Abstract available
CARVALHO FL, Lee J, Kalavros N, Zhou Y, et al Tumor-myeloid crosstalk drives therapy resistance in localized bladder cancer.
bioRxiv [Preprint]. 2025 Sep 15:2025.09.08.674862. PubMed Abstract available
SILVA LWPE, Almeida TC, Teixeira MSDS, Cerrutti CMV, et al Antiproliferative Effects of the Triterpene Ursolic Acid Natural Product in
Bladder and Ovarian Tumor Cell Lines.
Drug Dev Res. 2025;86:e70172. PubMed Abstract available
NAITO H, Taoka R, Zhang X, Hossain A, et al Enfortumab vedotin promotes PD-L1 expression in urothelial carcinoma via NF-kappaB
and STAT3 pathways highlighting mechanisms of immune evasion and potential for
combination therapy.
BMC Immunol. 2025;26:70. PubMed Abstract available
LEE S, Jung SY, Kus P, Bondaruk J, et al Dysregulated mitochondrial energy metabolism drives the progression of mucosal
field effects to invasive bladder cancer.
J Pathol. 2025 Sep 25. doi: 10.1002/path.6474. PubMed Abstract available
SAITO Y, Adomi S, Sakai K, Antonio De Velasco M, et al Evaluation of Telomerase Reverse Transcriptase (TERT) Promoter Mutations in
Photodynamic Diagnosis With 5-Aminolevulinic Acid False-Positive Sites in
Non-muscle-Invasive Bladder Cancer.
Cureus. 2025;17:e90860. PubMed Abstract available
ZHANG L, Zhou L, Xu W, Wu P, et al RNA m(5)C Modifications in the Development and Prognosis of Muscle-Invasive
Bladder Cancer.
Mol Carcinog. 2025 Sep 25. doi: 10.1002/mc.70042. PubMed Abstract available
ZHANG H, Huang W, Cai Z, Mou S, et al CCDC137 knockdown suppresses bladder cancer progression by downregulating SCD.
J Transl Med. 2025;23:1013. PubMed Abstract available
KANG H, Liu X, Ge D, Zeng Y, et al Revolutionizing bladder cancer research: Harnessing 3D organoid technology to
decode tumor heterogeneity and propel personalized therapeutics.
Biochim Biophys Acta Rev Cancer. 2025;1880:189454. PubMed Abstract available
WANG R, Fernandez K, Zelman B, Speiser J, et al Enfortumab vedotin-induced bullous dermatitis.
Dermatol Online J. 2025;31. PubMed Abstract available
AMIN A, Khalatbari F, Cheng L Genetic profiling of upper tract urothelial carcinoma: A necessity for precision
medicine.
Expert Rev Mol Diagn. 2025;25:695-708. PubMed Abstract available
CITGEZ S, Bulbul E, Ozden SB, Ilki FY, et al Benign ureteroenteric anastomotic stricture predictors in radical cystectomy
patients: A critical analysis focusing on the nutritional risk index and
postoperative urinary tract infection.
Urol Oncol. 2025 Aug 12:S1078-1439(25)00271. PubMed Abstract available
GUAN B, Wang G, Zhang H, Xia M, et al Does ureteral stent drainage prior to radical nephroureterectomy increase the
risk of intravesical tumor recurrence?
Urol Oncol. 2025;43:662. PubMed Abstract available
NICOLAZZINI M, Longoni M, Falkenbach F, Marmiroli A, et al Robot-assisted vs. open radical cystectomy: octogenarians vs. non octogenarians.
Eur J Surg Oncol. 2025;51:110345. PubMed Abstract available
RAUTIOLA J, Bjorklund J, Zelic R, Pellegrino F, et al Pelvic lymph-node dissections in bladder and prostate cancer surgery and the risk
of postoperative venous thromboembolism.
Eur J Surg Oncol. 2025;51:110326. PubMed Abstract available
JUSTE-ALVAREZ S, Garcia-Rayo Encina C, Gomez Del Canizo C, Hernandez-Arroyo M, et al Comparison of prognosis between primary and progressive muscle-invasive bladder
carcinoma: A prospective analysis of long-term outcomes after radical cystectomy.
Actas Urol Esp (Engl Ed). 2025;49:501815. PubMed Abstract available
ZHAO M, Zhang P, Xu J, Wang S, et al Small cell carcinoma with rhabdomyosarcomatous differentiation of the urinary
bladder: an integrated clinicopathological and molecular characterization of five
cases.
Virchows Arch. 2025;487:523-533. PubMed Abstract available
NEGISHI T, Kobayashi H, Furubayashi N, Morihara K, et al Health-Related Quality of Life in a Real-World Cohort of Patients with Advanced
Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors.
Oncology. 2025;103:921-929. PubMed Abstract available
WANG B, Bao EH, Jiang BL, Yang L, et al Signal mining and gender differences analysis of adverse events in NMIBC
treatment with gemcitabine and BCG bladder instillation based on the FAERS
database.
Expert Opin Drug Saf. 2025;24:1241-1248. PubMed Abstract available
CELIK M, Polat ME, Karaaslan M, Odabas O, et al Prediction of recurrence using hematologic and urinary markers in intravesical
Bacillus calmette Guerin treated bladder cancer.
Sci Rep. 2025;15:35415. PubMed Abstract available
MA TS, He HY [The application and advances of immunohistochemistry in the diagnosis and
differential diagnosis of bladder tumors].
Zhonghua Bing Li Xue Za Zhi. 2025;54:1110-1113. PubMed
RADIF D, Lindskrog SV, Nordentoft I, Birkenkamp-Demtroder K, et al The Impact of Kidney, Liver, and Immune Function on Circulating Tumor DNA
Detection in Muscle-invasive Bladder Cancer.
Eur Urol Oncol. 2025 Oct 9:S2588-9311(25)00246-9. doi: 10.1016/j.euo.2025. PubMed Abstract available
COLONNA G, Liesker D, M WB, Taurino M, et al Clinical Characteristics and Management of Infective Native Arterial Aneurysms
Associated with BCG Therapy for Bladder Cancer.
Ann Vasc Surg. 2025 Oct 8:S0890-5096(25)00659-4. doi: 10.1016/j.avsg.2025. PubMed Abstract available
ITO H, Koyama T, Tanahara S, Toda D, et al MRI findings of granulomatous prostatitis induced by intravesical Bacillus
Calmette-Guerin treatment for bladder cancer: a comparison with prostate cancer.
Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01871. PubMed Abstract available
TOKUDA PJK, Aizawa R, Iramina H, Ogata T, et al Online adaptive radiation therapy for muscle-invasive bladder cancer:
short-course and high-precision definitive treatment for elderly or medically
fragile patients.
Jpn J Radiol. 2025 Oct 10. doi: 10.1007/s11604-025-01885. PubMed Abstract available
MA Z, Hao Y, He W, Xie X, et al Comprehensive investigation identifies CPSF3 as a novel prognostic and oncogenic
biomarker in bladder cancer.
Discov Oncol. 2025;16:1847. PubMed Abstract available
ZHANG EZ, Millot JC, Balasubramanian A, Davis L, et al Persistent Sex Disparities in Bladder Cancer Diagnosis, an Analysis of National
Trends from 2012 to 2021.
Urol Pract. 2025 Oct 10:101097UPJ0000000000000904. PubMed Abstract available
WANG S, Ye D, Yang L, Cheng F, et al Distinct Clinicopathological Features of HER2-Negative, HER2-Low, and
HER2-Overexpressing Urothelial Carcinoma in a Large Chinese Cohort.
Cancer Med. 2025;14:e71289. PubMed Abstract available
MEYERS HM, Sharma J, Abdellatef AA, You M, et al Differential Expression of One-Carbon Pathway Enzyme ALDH1L1 Is Linked to
Tumorigenicity of Low-Grade Bladder Cancer Cells Through Metabolic Reprogramming.
Cancer Med. 2025;14:e71291. PubMed Abstract available
KIDESS M, Ebner B, Volz Y, Hermans J, et al [Therapy of non-muscle-invasive Bladder Cancer].
MMW Fortschr Med. 2025;167:40-41. PubMed
MOLINA-CERRILLO J, Catto J, Kamat AM, Necchi A, et al Revisiting Neoadjuvant Chemotherapy in Cisplatin-eligible Muscle-invasive Bladder
Cancer.
Eur Urol Oncol. 2025 Oct 8:S2588-9311(25)00242-1. doi: 10.1016/j.euo.2025. PubMed Abstract available
KAWAHARA T, Nitta S, Shiga M, Nagumo Y, et al Second opinions and pathological review impact the clinical management of
patients with muscle-invasive bladder cancer.
World J Urol. 2025;43:602. PubMed Abstract available
LIU H, Chen J, Zhu Q, Liu H, et al Efficacy of Disitamab Vedotin and Immune Profiles in High-Risk
Non-Muscle-Invasive Bladder Cancer With HER2 Overexpression.
MedComm (2020). 2025;6:e70427. PubMed
HUSSAIN H, Reid U, Nagtode S, Shameem F, et al Macroplastique, a urethral bulking agent for stress urinary incontinence
mimicking a bladder tumour.
BMJ Case Rep. 2025;18:e263166. PubMed Abstract available
RETRACTION: Examining the Causal Association between Psoriasis and Bladder
Cancer: A Two-sample Mendelian Randomization Analysis.
Skin Res Technol. 2025;31:e70252. PubMed
SUGINO Y, Bao X, Sekito S, Miyachi S, et al Zebrafish Xenograft Model for Predicting Cisplatin Efficacy in Muscle-Invasive
Bladder Cancer.
Cancer Sci. 2025 Oct 8. doi: 10.1111/cas.70217. PubMed Abstract available
MAQBOOL A, Aziz W, Iqbal S, Ather MH, et al Effectiveness of Video-Based Instructions on Urostomy Self-Care in Patients
Undergoing Radical Cystectomy with Ileal Conduit Urinary Diversion.
J Coll Physicians Surg Pak. 2025;35:1345-1349. PubMed Abstract available
TONG H, Sun Y, He W Commentary on "Complex causal association between immune cell phenotypes and
bladder cancer: a mendelian randomization and mediation study".
Int J Surg. 2025 Oct 7. doi: 10.1097/JS9.0000000000003587. PubMed
DULF DV, Ravegnini G, Giorgi FM, Burnar AL, et al The miRNA-immune axis in bladder cancer: systematic evidence for a new era of
immunotherapy precision.
Front Immunol. 2025;16:1639334. PubMed Abstract available
MARTINSON T, Hare CB, Kirmaier A, Presti JC, et al Disseminated BCGosis After Intravesical BCG Installation for Bladder Cancer.
Case Rep Infect Dis. 2025;2025:9532859. PubMed Abstract available
ZHANG L, Li F, Liu L, Cao J, et al Prevalence and prognostic value of sarcopenia in patients with bladder cancer
undergoing radical cystectomy: a systematic review and meta-analysis.
Front Oncol. 2025;15:1642833. PubMed Abstract available
GUI Q, Guo H, Liu T, Wen X, et al Prognostic risk factors and the role of systemic inflammatory response index in
predicting outcomes for non-muscle-invasive bladder cancer.
Front Oncol. 2025;15:1646723. PubMed Abstract available
CHOU KY, Chang AC, Hwang TI, Tsai TF, et al ABCC6 Transporter Contributed to Cisplatin Resistance on Bladder Cancer.
Int J Med Sci. 2025;22:3895-3905. PubMed Abstract available
DI Y, Zhang L, Zhao L, Yin L, et al Influencing Factors and Risk Prediction Model Construction of Urinary Tract
Infections in Patients with Bladder Cancer.
Res Rep Urol. 2025;17:383-399. PubMed Abstract available
PECE A, Lovato G, Cela I, Mercatelli A, et al Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a
novel urinary disease biomarker.
Mol Oncol. 2025 Oct 5. doi: 10.1002/1878-0261.70140. PubMed Abstract available
CHEN AL, Zhang CA, Ogunkeye J, Ge TJ, et al Differences in postoperative communication patterns among patients with limited
English proficiency following radical cystectomy for bladder cancer.
Urol Oncol. 2025 Oct 3:S1078-1439(25)00346-1. doi: 10.1016/j.urolonc.2025. PubMed Abstract available
MOHAMMADNEJAD F, Rajabi N, Doustvandi MA, Nobari SA, et al Photodynamic therapy with zinc phthalocyanine enhances cisplatin sensitivity of
human muscle-invasive bladder cancer cells by downregulation of PI3K/AKT/mTOR
signaling pathway.
Cancer Treat Res Commun. 2025;45:101007. PubMed Abstract available
LONGONI M, Falkenbach F, Marmiroli A, Le QC, et al Effect of neoadjuvant chemotherapy on years of life lost in radical
cystectomy-treated T2N0M0 bladder cancer patients.
World J Urol. 2025;43:591. PubMed Abstract available
LOTEM M, Sharkia I, Azria B, Harpenas E, et al Urine cf-nucleosomes: A non-invasive window into human physiology and disease.
Cell Genom. 2025;5:100974. PubMed Abstract available
BROUZES H, Ourfali S, Fassi-Fehri H, Benoit-Janin M, et al Predicting recurrence and progression in NMIBC: A multi-event and temporal
analysis approach.
Fr J Urol. 2025;35:102921. PubMed Abstract available
IIZUKA T, Ishikawa A, Motoi N, Kanda H, et al Immunostaining for polycomb group protein EZH2 as a diagnostic tool to
differentiate urothelial carcinoma in situ from benign lesions.
Hum Pathol. 2025;160:105823. PubMed Abstract available
NISHIO K, Hirosuna K, Uchimoto T, Niigawa H, et al Real-world Outcomes of Enfortumab Vedotin in Elderly Patients With Metastatic
Urothelial Carcinoma.
Anticancer Res. 2025;45:4575-4583. PubMed Abstract available
RUBIO-BRIONES J, Guerrero Ramos F, Mercade Sanchez A, Bezana Abadia I, et al External validation of the Uromonitor(R)-version 2 urine test as a biomarker for
optimisation of non-muscle-invasive bladder cancer management.
BJU Int. 2025 Oct 1. doi: 10.1111/bju.70010. PubMed Abstract available
WU J, Cheng B, Song Y, Cheng J, et al Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4-Targeted
Antibody-Drug Conjugate Enfortumab Vedotin in Bladder Cancer.
Cancer Res. 2025 Oct 9. doi: 10.1158/0008-5472.CAN-25-0024. PubMed Abstract available
PRADERE B, Schuit M, Guerrero-Ramos F, Shariat SF, et al Side effect management and procedural best practices with indwelling intravesical
drug-releasing systems in the treatment of bladder cancer: recommendations from
expert panels.
Curr Opin Urol. 2025 Oct 8. doi: 10.1097/MOU.0000000000001350. PubMed Abstract available
STOCKEM CF, van Dorp J, van Dijk N, Vis DJ, et al Final clinical analysis of pre-operative ipilimumab and nivolumab in locally
advanced urothelial cancer and exploration of tumor-draining lymph node
composition: The NABUCCO trial.
Eur J Cancer. 2025;229:115731. PubMed Abstract available
SHI Z, Yang S, Yang Y Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder
Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled
DaBlaCa-15 Trial. Eur
Eur Urol. 2025 Sep 27:S0302-2838(25)04682-2. doi: 10.1016/j.eururo.2025. PubMed
ROVIELLO G, Antonuzzo L Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant
Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer:
A Phase 2 Trial. Eur
Eur Urol. 2025 Sep 27:S0302-2838(25)04695-0. doi: 10.1016/j.eururo.2025. PubMed
DREYER T, Jensen JB Reply to Heidi Pharo, Hege Marie Vedeld, Rolf Wahlqvist, and Guro E. Lind's
Letter to the Editor re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of
the Xpert Bladder Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in
High-grade
Eur Urol. 2025 Sep 25:S0302-2838(25)04642-1. doi: 10.1016/j.eururo.2025.09.4129. PubMed
PHARO H, Vedeld HM, Wahlqvist R, Lind GE, et al Re: Thomas Dreyer, Simone Brandt, Knud Fabrin, et al. Use of the Xpert Bladder
Cancer Monitor Urinary Biomarker Test for Guiding Cystoscopy in High-grade
Non-muscle-invasive Bladder Cancer: Results from the Randomized Controlled
DaBlaCa-15 Trial. Eur
Eur Urol. 2025 Sep 24:S0302-2838(25)04646-9. doi: 10.1016/j.eururo.2025. PubMed
LI X, Wang X, Zhang G Re: Ruben Raychaudhuri, Ali Raza Khaki, Mary W. Redman, et al. Neoadjuvant
Pembrolizumab and Accelerated Methotrexate, Vinblastine, Doxorubicin, and
Cisplatin in Nonurothelial Histologic Subtypes of Muscle-invasive Bladder Cancer:
A Phase 2 Trial. Eur
Eur Urol. 2025 Sep 24:S0302-2838(25)04654-8. doi: 10.1016/j.eururo.2025. PubMed
BELLMUNT J, Powles T, Park SH, Voog E, et al Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term
Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph
Node-only Disease.
Eur Urol. 2025;88:331-338. PubMed Abstract available
GALSKY MD, van der Heijden MS, Powles T, Claps M, et al Characterization of Patients with Lymph Node Only Metastatic Urothelial Carcinoma
Treated with Nivolumab Plus Gemcitabine-Cisplatin Versus Gemcitabine-Cisplatin
Alone from the CheckMate 901 Trial.
Eur Urol. 2025;88:325-330. PubMed Abstract available
DANESHMAND S, Zaucha R, Catto JWF, Tran B, et al Erdafitinib in Patients with High- and Intermediate-risk Non-muscle-invasive
Bladder Cancer: Final Analysis of THOR-2 Study.
Eur Urol. 2025 Oct 7:S0302-2838(25)04702-5. doi: 10.1016/j.eururo.2025.09.4152. PubMed Abstract available
KWONG JCC, Al-Daqqaq Z, Chelliahpillai Y, Lee S, et al Development and International Evaluation of an Artificial Intelligence-based
Model (PROGRxN-BCa) Using the World Health Organization 2004/2022 Grading System
to Predict Progression Risk and Improve Substratification for Non-muscle-invasive
Bladder Can
Eur Urol. 2025 Oct 7:S0302-2838(25)04688-3. doi: 10.1016/j.eururo.2025.09.4145. PubMed Abstract available
MEGHANI K, Yu Y, Frydenlund N, Li EZ, et al Genomic and Transcriptomic Profiling of High-risk Bladder Cancer Reveals Diverse
Molecular and Microenvironment Ecosystems.
Eur Urol. 2025 Oct 6:S0302-2838(25)04677-9. doi: 10.1016/j.eururo.2025.09.4138. PubMed Abstract available
INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab
Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
Int J Urol. 2025;32:1449-1459. PubMed Abstract available
AKPINAR C, Erkartal S, Soydas T, Demirel D, et al Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing
Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.
Int J Urol. 2025;32:1395-1402. PubMed Abstract available
YENTUR S, Canitez IO, Dusunus YE, Sahin S, et al Simultaneous transurethral resection of the prostate and bladder tumor: a safety
and efficacy analysis.
Int Urol Nephrol. 2025;57:3219-3226. PubMed Abstract available
MEEKS JJ, van der Heijden MS, Powles T, Galsky MD, et al PD37-09 The First Report Of Disease-Free Survival Analyses From The Niagara Trial
Of Perioperative Durvalumab Plus Neoadjuvant Chemotherapy In Muscle-Invasive
Bladder Cancer: Erratum.
J Urol. 2025;214:556. PubMed
DONAHUE TF, Assel M, Cha EK, Goh A, et al Evaluating Benefits of Peristomal Mesh Placement at the Time of Radical
Cystectomy and Ileal Conduit Formation: A Phase 3, Randomized Controlled Trial.
J Urol. 2025;214:487-495. PubMed Abstract available
NAKANISHI Y, Nakanishi Y, Ogasawara RA, Imasato N, et al Separated Transfixing Uretero-Enteral Anastomosis Method in Robot-Assisted
Radical Cystectomy with Ileal Conduit: Early Induction Experience.
Urol Int. 2025;109:546-552. PubMed Abstract available
BAHLBURG H, Bahlburg H, Rausch P, Silberg M, et al Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic:
Fact or Fiction?
Urol Int. 2025;109:501-507. PubMed Abstract available
PATTOU M, Ochoa A, Goujon A, Verine J, et al Outpatient Transurethral Resections of Bladder Tumors: Insights from the Largest
Cohort to Date.
Urol Int. 2025;109:471-477. PubMed Abstract available
CHEN B, Zhou Y, Li Z, Chen J, et al A study on predicting recurrence of non-muscle-invasive bladder cancer within
2 years using mp-MRI radiomics.
BMC Cancer. 2025;25:1497. PubMed
LIU S, Lei K, Li G, Zheng P, et al The integration of transcriptomics and metabolomics elucidates the antitumor
mechanisms of mycophenolic acid in bladder cancer cells.
BMC Cancer. 2025;25:1463. PubMed Abstract available
YEH CC, Tsai PC, Song YD, Low YS, et al Metformin as an anti-cancer agent against bladder cancer acts via PD-L1
downregulation in an orthotopic mouse model.
BMC Cancer. 2025;25:1534. PubMed Abstract available
KANAAN MR, Schmitz J, Braesen JH, Kuczyk MA, et al Comparison of molecular profiles (Nectin-4 and TROP-2) in upper tract urothelial
carcinoma with a positive history of urinary bladder cancer vs. UTUC only in the
era of ADCs.
BMC Cancer. 2025;25:1525. PubMed Abstract available
ABOULHODA BE, Omar AM, Elfarrash S, Alghamdi MA, et al Novel anticancer effect of substituted imidazole derivatives against urothelial
carcinoma: integrating In vitro screening and molecular docking for target
kinases.
BMC Cancer. 2025;25:1524. PubMed Abstract available
